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A HIGH incidence of breast cancer has been found in a series of 92 female
thyroid cancer patients. Careful examination of the literature has failed to
reveal reports of similar findings in other thyroid cancer series.
During the twenty-year period 1945-1964, 106 patients with histologically
proven thyroid cancer attended the Royal Free Hospital, London. Ninety-two
ofthese were women and eight ofthese female patients also hadprimary carcinoma
of the -breast (8.7 per cent). Relevant details of their case histories are shown
in Table I. In three of these patients the breast neoplasm preceded the thyroid
cancer; in three cases the opposite occurred and in the other two, both lesions
were found at the same time.
One patient (Case No. 5) was thyrotoxic before treatment. She received eight
months Carbimazole therapy and then had a subtotal thyroidectomy. Histolo-
TABLE I.-Thyroid and Breast Cancer
Breast
Case Age at Date of
No. diagnosis operation Histology
65
49
49
55
1963 Carcinoma
simplex
1950 Spheroidal
cell
carcinoma
1957 Adeno-
carcinoma
1938 ?
5 . 42 1965 Mucus-
secreting
carcinoma
6 . 32 1946 Intraduct
adeno-
carcinoma
7 . 52 1941 Spheroidal
cell
carcinoma
8 . 76 1947 Anaplastic
scirrhous
carcinoma
Age at Date of
diagnosis operation Histology
53
49
1951 Papillary
carcinoma
1950 Papillary
carcinoma
47 1955 Papillary
carcinoma
77 1960 Papillary
carcinoma
37 1961 Papillary
carcinoma
48 1962 Papillary
carcinoma
63
76
1952 Anaplastic
carcinoma
Thyroid
I-
A
I- * 5
B.M.R. and 131I up-
Dates take and
dates
1952: -7% -
1962: +1%
1950: -8% -
1956:
1960:
1961:
1961:
1963:
1965:
1962:
40%
+1%
+29%
-14%
+30%
-30%
-1%
1952: -2%
1955
normal
1960
normal
1961
high
1962
low
1952
normal
1947 Spindle
cell
sarcoma
1 .
2 .
3 .
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gical examination revealed a nodule ofpapillary adenocarcinoma in a hyperplastic
gland. Following the operation her basal metabolic rate fell to 14 per cent
and she was given 0.2 mg. 1-thyroxine daily for the next two years. Mild symp-
toms suggestive of hyperthyroidism recurred and her basal metabolic rate was
found to be +30 per cent. In view of this the 1-thyroxine was discontinued.
Two years later she noticed a lump in the right breast. This was a mucus-
secreting carcinoma with metastases in the right axillary lymph nodes and was
treated by radical mastectomy, Cyclophosphamide therapy and radiotherapy.
Her basal metabolic rate at the time of discovery of the breast neoplasm was
30 per cent.
The other seven patients were clinically euthyroid and basal metabolic rate
estimations were all in the lower part of the normal range. Radioactive iodine
uptake studies were normal in three patients, (Cases No. 3, 4 and 7), low in one
patient (No. 6) and were not done in the other three (No. 1, 2 and 8).
In six of these patients the thyroid carcinoma was of the papillary type.
DISCUSSION
An 8-7 per cent incidence of breast carcinoma in this series of thyroid cancer
patients contrasts with a very much lower incidence in comparable age groups
of the general population of women in England and Wales, as is shown by the
figures from the National Cancer Register in Table II.
TABLE II.- Registrations of Carcinoma of the Breast-England
and Wales 1962
Rate per
Number of 100,000 women
Age group registrations in age group
0-14 . 1
15-24 12 . 0 4
24-34 . 314 . 10*8
35-44 1757 . 55.2
45-54 3339 103.1
55-64 3554 . 120-7
65-74 . 2981 . 139-6
75 and over . 2202 . 174.7
not stated . 16
35 and over . 13833 . 107-8
Expressed as a per cent rate (to compare with the 8*7 per cent quoted above)
the incidence in 1962 was not higher than 0-2 per cent in any age group and over
the whole range from age 35 was only 0-1 per cent. In this comparison 1962
registrations have been used because coverage of the registration system was less
complete in earlier years. The year 1962 is not considered to be incomparable
regarding breast cancer incidence, with the period of twenty years to which the
thyroid series relates. So far as mortality reflects incidence, there has been no
significant change in the two recent decades. The death rate per million living
-for females which was 389 in 1962, was 363 in 1952 and 336 in 1942 but when
account is taken of the ageing of this population in the period, this apparent rise
is reduced to insignificance. Certainly 0 1 per cent is not likely to be an under-
statement of the incidence of breast cancer in the general female population of
age 35 and over. Even allowing for the fact that the 8-7 per cent incidence of
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breast cancer in the series is subject to a 95 per cent confidence interval ranging
from 2-8 to 14-6 per cent, it is clear that there is a significant excess incidence of
breast cancer in this series.
Although we have encountered no other reports of a high incidence of breast
carcinoma in patients with thyroid cancer. the literature contains many references
to the relationship between breast cancer and thyroid disease in general.
Evidence on the subject of a causal relationship between thyroid dysfunction
and breast cancer may be summarised as follows:
1. Geographical coincidence
Statistics have shown that areas in which goitres are common tend to have a
breast cancer mortality rate which is high. The reverse is true in areas where
thyroid disease is uncommon (Bogardus and Finley, 1961).
2. Clinical coincidence
Bogardus and Finley (1961) reported that of 79 patients with breast cancer
42 also had some abnormality of the thyroid gland. Goitres were present in
37 cases and the others had either had a thyroid operation or thyroid therapy in
the past. Most oftheir patients were euthyroid, none was hyperthyroid. Ellerker
(1956) reported a 7-6 per cent incidence of goitres in 157 cases of breast cancer.
In another group of 100 women between 40 and 60 years old, who had previously
undergone thyroidectomy, he found a 6 per cent incidence of breast carcinoma.
Only one of these thyroid operations had been for cancer, 30 were for thyrotoxi-
cosis and the remaining 69 for various types of non-toxic goitre. On the other
hand, Humphrey and Swerdlow (1964) found no incidence of breast carcinoma
in a 12-year follow-up of 196 patients who had previously had thyroidectomy.
Their finding of previous thyroid disease in 12 per cent of patients with breast
cancer agrees with that of Repert (1952) who states that this is 10 times the
expected rate for the incidence of thyroid disease.
Larsson, Sundbom and Astedt (1963) reported co-existent gynaecomastia in
two patients with thyrotoxicosis and one with an active "malignant thyroid
adenoma ". During treatment of the thyrotoxicosis the gynaecomastia disap-
peared completely in one case. Mastectomy was performed on the other two
patients. They found an increased urinary output of 17-ketogenic steroids,
gonadotrophins and oestrogens and suggested that these may have been due to
the action of the thyrotrophic hormone of the pituitary gland on the adrenal
cortex. There was no evidence of liver dysfunction in these patients.
3. Evidence from investigations of thyroid function
Using radioactive iodine (1311) Edelstyn, Lyons and Welbourn (1958) studied
thyroid function in patients with breast cancer and concluded that, whereas it
was normal in patients with localised breast carcinoma, thyroid function was
significantly lowered in those with widespread metastases. They suggested that
this could be due either to the metastases depressing thyroid activity or to the
reduced thyroid function favouring the distant spread of the cancer.
Later investigations of this sort (Reeve et al., 1961 ; Capelli and Margottini,
1964) failed to confirm any statistically significant alteration of thyroid function
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in patients with widespread breast carcinoma. Dargent, Berger and Lahneche
(1962) reported that thyroid uptake of radioactive iodine and the serum protein-
bound 131I levels were significantly higher in patients with actively-growing
breast cancer than in a normal control group. These abnormalities of thyroid
function apparently disappeared after excision of the breast tumours and re-
appeared with local or metastatic recurrences.
At present it is not possible to reconcile these apparently contradictory findings
and further investigations of thvroid function in breast cancer are obviously
needed in order to resolve this problem.
4. Results of treatment of breast cancer with thyroid hormones
Beatson (1896) was the first to claim success in the treatment of advanced
breast carcinoma by using thyroid extract in addition to oophorectomy. Loeser
(1954) reported good results from the use of thyroid hormone as a prophylactic
against recurrence after radical operations for breast and genital cancers. He
also stated that thyroid hormone, given in massive dosage in cases of inoperable
carcinoma of the breast and genital organs, slowed down their rate of growth.
More recent investigations to determine the value of thyroid hormone in the
prevention (Lyons and Edelstyn, 1965) and treatment (Stoll, 1962; Emery and
Trotter, 1963) of breast cancer recurrences have not confirmed these claims.
However, these findings do not invalidate the probability ofa definite relationship
between breast cancer and thyroid dysfunction. Even if an abnormal endocrine
environment is a factor in the development of a cancer, it does not automatically
follow that correction of that hormonal environment will suppress that neoplasm
once it has reached the stage of being an autonomous malignant growth.
5. Evidence from necropsy studies
Sommers (1955) examined endocrine glands anid target organs from 207
women who died of breast cancer and 248 control cases. Hyperplastic changes
in the ovarian stroma, endometrium, uninvolved breast epithelium, anterior
pituitary cells and adrenal cortex cells were significantly more numerous among
the breast cancer cases as compared with the controls. In contrast, atrophy of
the thyroid gland was found in the majority of breast cancer cases and this was
not related to weight loss of these patients. Only 14 per cent of the breast
carcinoma patients had histologically normal thyroids as compared to 65 per cent
ofthe control cases. In view ofthese findings Sommers suggested that the series
of events which occurs in many women with breast cancer is: thyroid atrophy,
pituitary basophil hyperplasia, increased output of thyrotrophins and gonado-
trophins and resultant ovarian stromal hyperplasia. This in turn leads to con-
tinuous oestrogenic stimulation of the breast epithelium. Additional oestrogenic
output by the adrenal'oortex may also follow pituitary hyperplasia.
6. Evidence from experiments on animals
Purves and Griesbach (1951) showed that the thyroid-stimulating-hormone
(T.S.H.) is produced by a particular group ofbasophil cells in the adenohypophysis
and that the follicle-stimulating-hormone is formed by other closely adjacent but
histologically distinct basophil cells. Furth and Clifton (1957) described how
673L. J. CHALSTREY AND B. BENJAMIN
neoplasia of individual pituitary cell-types could be separately induced. They
referred to this as biological dissection of the pituitary gland into its functional
units by development ofmonomorphic, functional, responsive tumours. Basophil
tumours were developed which yielded a tremendous output of T.S.H. and in
addition to hyperplastic and neoplastic thyroid changes, simultaneous gonado-
trophic effects on the ovaries were observed. The resultant increase in oestrogen
output caused mammary hyperplasia.
Thus the geographical and clinical coincidence of breast cancer and thyroid
disease indicate that they have a definite relationship. The necropsy studies and
experimental work briefly described suggest that this relationship exists at the
level of the pituitary gland. The role of thyroid deficiency in stimulating exces-
sive T.S.H. output is well recognised as an important factor in the production of
experimental thyroid cancers (Griesbach and Purves, 1945 ; Bielschowsky, 1949,
1955; Doniach, 1953, 1956, 1958; Axelrad and Leblond, 1955). There is also
much evidence that excessive T.S.H. output stimulates the growth of some
human thyroid cancers. However, radioactive iodine studies have failed to
establish that thyroid function is depressed in most cases of breast cancer. It
therefore seems possible that some other, as yet undiscovered, pituitary hormonal
dysfunction is responsible. The high incidence of breast cancer in the series of
cases reported here suggests that this dysfunction is more marked in thyroid
cancer than in other forms of thyroid disease.
PRACTICAL CONSIDERATIONS
Although the precise nature of this relationship between breast cancer and
thyroid disease is not yet understood, there are two important prophylactic
measures which can be adopted in the management of patients with thyroid
disease.
Firstly, in order to avoid pituitary overstimulation, no patient should be
allowed to remain in a hypothyroid state following thyroidectomy. This requires
careful, long-term follow-up of these patients.
Secondly, in view ofthe high incidence of breast carcinoma in patients treated
for thyroid cancer, the routine follow-up of the latter should include examination
of the breasts.
SITMMARY
(1) A high incidence of breast carcinoma in a series of women with thyroid
cancer is reported.
(2) Evidence for a causal relationship between breast cancer and thyroid
disease is summarised and discussed.
(3) The importance of preventing the development of a hypothyroid state
after thyroidectomy and the importance of routine examination of the breasts
in patients treated for thyroid cancer are emphasised.
We are grateful to the Surgeons of the Royal Free Hospital who permitted us
to study these patients and especially to Miss Phyllis George, Surgeon in charge
of the Thyroid Clinic.
The help of the General Register Office in supplying statistical data is also
gratefully acknowledged.
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